Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

AyoxxA Biosystems Closes Series A Financing Round

Published: Thursday, September 20, 2012
Last Updated: Thursday, September 20, 2012
Bookmark and Share
2.6 million Euro financing will accelerate development of cutting-edge technology for protein analysis.

AyoxxA Biosystems has announced that it has closed a 2.6 million Euro Series A financing round.

The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.

The funds raised will be used to drive the further development of AyoxxA’s proprietary platform technology and the scale-up of production of its novel bead-based biochips as the company moves towards commercialization.

AyoxxA’s technology is aimed at transforming the throughput and accuracy of protein analysis to deliver the analytical power now seen only for DNA arrays.

The platform is based around proprietary In-situ Encoded Bead-based Arrays (IEBA) which allow the simultaneous measurement of multiple proteins from minute samples.

Unlike current bead-based microarrays, AyoxxA’s IEBA need no physical label to allow multiplex analysis and thus hugely reduce the complexity of downstream analysis while increasing the number of individual proteins that can be analyzed at the same time.

The arrays are designed to be readily adaptable to standard high throughput screening systems and offer the potential of tens of thousands of ELISA assays in a single well of a biochip.

Dr. Andreas Schmidt, CEO of AyoxxA, said: “This fundraising provides Ayoxxa with the resources to significantly accelerate the scale-up of production of our unique bead-based biochips and, through the expansion of our base in Cologne, prepare to bring our technology to market. We believe our technology can revolutionize protein analysis and with our growing presence in Europe combined with our continued access to the world-class science in Singapore we are uniquely positioned to deliver on that promise.”

Dr. Regina Hodits, General Partner of Wellington Partners Venture Capital, commented: “AyoxxA’s technology has the potential to become the new standard for the precise, fast, and cost effective analysis of multiple protein-protein interactions in limited sample volumes. This will allow the company to initially address a research market worth hundreds of millions of dollars and longer term reach into pharmaceutical screening and ultimately diagnostics. In Andreas Schmidt and co-founder and CSO Dieter Trau, we have a very entrepreneurial team which has already rapidly brought the AyoxxA technology from the idea stage to first proof-of-concept. We look forward to working with the company as it builds on this excellent foundation and delivers benefits to its customers and investors.”

Rainer Christine, Chairman of the Board of AyoxxA, said: “It is exciting to be investing in AyoxxA at a critical point in the Company’s development. I have followed its story closely since it was founded by Andreas and Dieter, who had invented the technology as a Professor of Bioengineering at the National University of Singapore. I am impressed by the progress made in advancing the technology and by the potential it has to address significant markets. I hope to bring the experience I gained in successfully building amaxa to the Board and Company as it grows.”

Dr. Matthias Dill, HTGF investment manager, added: "We are pleased to have played a role in building a consortium of experienced investors to optimally support AyoxxA as it benefits further from its position as part of two high tech countries. The company’s choice to base its headquarters in Cologne highlights the continuing attractiveness of Germany as a site for building new companies and growing international businesses.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AYOXXA BIOSYSTEMS Appoints Dr. Gerald Möller as Chairman of the Board
Company directs its powerful multiplex platform to unlock the power of proteomics in precision medicine.
Tuesday, September 15, 2015
AYOXXA and Grünenthal Completed Research Collaboration
Successful validation of protein multiplexing technology platform.
Thursday, June 25, 2015
Scientific News
Biomarker Predicting Transplant Complications May be Key to Treating Them
A protein that can be used to predict if a stem cell transplant patient will suffer severe complications may also be the key to preventing those complications, an international research team based at the Indiana University School of Medicine reported Wednesday.
New Protein Cleanup Factors Found to Control Bacterial Growth
UMass Amherst researchers characterize previously mysterious proteolysis factors.
Proteins with ALS, Cancer Role Do Not Assume a Regular Shape
Our cells contain proteins, essential to functions like protein creation and DNA repair but also involved in forms of ALS and cancer, that never take a characteristic shape, a new study shows.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
How a Molecular Motor Untangles Protein
Diseases such as Alzheimer’s, Parkinson’s and prion diseases, all involve “tangled” proteins.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
How Cell Growth Triggers Cell Division
Researchers in Jan Skotheim's lab have discovered a previously unknown mechanism that controls how large cells grow, an insight that could one day provide insight into attacking diseases such as cancer.
Probing the Forces Involved in Creating The Mitotic Spindle
Scientists at The Rockefeller University reveal new insights into the mechanical forces that govern elements of the mitotic spindle formation.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos